Bio-Path Holdings, Inc. (BPTH) Initiates Development of Liposomal Grb-2 for Triple Negative and Inflammatory Breast Cancers
7/22/2013 9:34:28 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
HOUSTON--(BUSINESS WIRE)--Bio-Path Holdings, Inc., (OTCQX:BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it is initiating preclinical testing of its lead product candidate, BP-100-1.01 (Liposomal Grb-2), into two additional indications: triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates. Bio-Path is currently evaluating Liposomal Grb-2 in a Phase I clinical trial as a systemic treatment for blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS). The clinical trial and research is being conducted at The University of Texas MD Anderson Cancer Center (MD Anderson Cancer Center).
Help employers find you! Check out all the jobs and post your resume.
comments powered by